cdx-3379
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 27, 2018 (NCT03254927)
Timeline
Indications
Mechanism of action
Receptor tyrosine-protein kinase erbB-3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650292 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03580382 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2018 | New York University |
| NCT03254927 | Phase 2 | Mar 27, 2018 | Celldex Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 1 | 1 | 1 | 2018 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1